PVLA
PALVELLA THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$150.56
−2.44%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$153.79
From 52W high−4.57%
Volume628432.00
Market cap$2.17B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$153.79
From 52W high
−4.57%
Volume
628432.00
Market cap
$2.17B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−38.4x
P/E (TTM)
—
RSI (14)
51.8
MomentumView details →
1D Return
−2.44%
YTD Return
+45.16%
SummaryUpdated Jun 1, 2026
Palvella Therapeutics, Inc. (NASDAQ:PVLA) is a clinical-stage biopharmaceutical company founded in 2015 and based in Wayne, Pennsylvania. The company specializes in developing novel therapies for patients with serious and rare genetic skin diseases. Since its inception, Palvella has focused on advancing its lead product candidate through clinical trials, with a particular emphasis on treating conditions driven by the mTOR (mechanistic target of rapamycin) pathway. The company went public in 2015 and continues to operate as a development-stage biotechnology firm without commercial revenue.
Similar companies
Latest newsMore news →
Palvella Therapeutics director George M. Jenkins sold 27,500 shares of the company's common stock for about $4.17 million between September 11 and September 15, 2026, under a pre-arranged Rule 10b5-1 trading plan.5d agoPalvella Therapeutics completed the rolling submission of a New Drug Application to the FDA for QTORIN rapamycin for the treatment of microcystic lymphatic malformations.20d agoPalvella Therapeutics announced it is on track to complete its NDA submission for QTORIN rapamycin in microcystic lymphatic malformations during the second half of 2026, with potential FDA approval targeted for the first half of 2027.45d ago